Topics
Health
Pharma
Biotech
Politics & Policy
Health Tech
In the Lab
Business
Artificial Intelligence
Opinion
First Opinion
The Pharmalot View
Adam’s Take
Podcast
Newsletters
Events
Upcoming Events
STAT Summit
Webinars
STAT Expert Advantage
Reports
Log in
Subscribe
Newsletters
Try STAT Plus
Newsletters
Try STAT Plus
Valeant Pharmaceuticals
Pharmalot
Pharmalot, Pharmalittle: FTC is ‘aware’ of concerns over possible Mylan antitrust violations
By
Ed Silverman
Pharmalot
Feds charge former Valeant and Philidor execs with fraud
By
Ed Silverman
advertisement
Pharmalot
Pharmalot, Pharmalittle: Valeant may change its name to create a new image
By
Ed Silverman
advertisement
Pharmalot
Pharmalot, Pharmalittle: Glaxo CEO looks for drug prices to fall no matter who is president
By
Ed Silverman
Pharmalot
Pharmalot, Pharmalittle: Valeant sued by Sprout investors over female libido pill
By
Ed Silverman
Pharmalot
Pharmalot, Pharmalittle: Valeant looks to sell Salix to lessen debt load
By
Ed Silverman
Pharmalot
Former Valeant CEO and CFO are being investigated by the feds
By
Ed Silverman
advertisement
Pharmalot
Congressman calls for probe into Valeant’s pricing of lead poisoning drug
By
Ed Silverman
advertisement
Pharmalot
Pharmalot, Pharmalittle: Pfizer will sell a biosimilar version of Remicade next month
By
Ed Silverman
Pharmalot
Pharmalot, Pharmalittle: Drug makers are making huge bets on some cancer meds
By
Ed Silverman
Pharmalot
Huge Valeant price hike on lead poisoning drug sparks anger
By
Ed Silverman
Pharmalot
Rising drug prices are making hospitals feel ill
By
Ed Silverman
Pharmalot
Up and down the ladder: The latest comings and goings
By
Ed Silverman
Pharmalot
Valeant avoids double-digit price hikes with 9.9 percent increases
By
Ed Silverman
Pharmalot
Up and down the ladder: The latest comings and goings
By
Ed Silverman
Pharmalot
Pharmalot, Pharmalittle: Pfizer pays $14 billion for Medivation and its prostate cancer drug
By
Ed Silverman
Pharmalot
Valeant gets poor grades for its Addyi female libido pill
By
Ed Silverman
Pharmalot
Up and down the ladder: The latest comings and goings
By
Ed Silverman
Pharmalot
Pharmalot, Pharmalittle: Valeant under criminal investigation for defrauding insurers
By
Ed Silverman
Pharmalot
Pharmalot, Pharmalittle: Valeant reorganizes and maintains earnings forecast
By
Ed Silverman
Pharmalot
Pharmalot, Pharmalittle: Valeant overhauls part of its management team
By
Ed Silverman
Pharmalot
Pharmalot, Pharmalittle: Valeant losing a crucial revenue tool
By
Ed Silverman
The Pharmalot View
Pharma trade group says price gougers are outliers, but then accepts two more
By
Ed Silverman
Pharmalot
Pharmalot, Pharmalittle: FDA overlooks troubles at Chinese supplier to avoid shortages
By
Ed Silverman
Pharmalot
Pharmalot, Pharmalittle: Novartis stops making TB drugs in Pakistan, prompting fear of a health crisis
By
Ed Silverman
Pharmalot
Pharmalot, Pharmalittle: FDA reviewers say Valeant drug carries suicide risks
By
Ed Silverman
Pharmalot
Pharmalot, Pharmalittle: Medivation to start takeover talks with Sanofi and others
By
Ed Silverman
Pharmalot
Up and down the ladder: The latest comings and goings
By
Ed Silverman
Pharmalot
Pharmalot, Pharmalittle: India inspects 200 drug makers for poor-quality meds
By
Ed Silverman
Next Page »
Your daily dose of news in health and medicine
Industry
Academia
Advertising/Marketing
Advocacy
Biotech
Consultancy/Firm
Financial Services
Government
Healthcare Payer
Healthcare Provider
Media
Medical Device
Non-profit
Pharma
Technology
Privacy Policy
Leave this field empty if you're human:
